HMGB1 and breast carcinoma: DOC treatment drives HMGB1 release, acting as a potential antitumor immune response inducer in metastatic breast cancer cells [40, 41], but the response of NSCLC patients to neoadjuvant chemotherapy (NCT) was unknown.